Ma Varney
Research Subjects
Ma Varney has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Newman-Tancredi
Neurolixis SAS, 2 rue Georges Charpak, 81100 Castres, France
3 shared publications - A Vidinha-Mira2 shared publications
- Andreia Teixeira-Castro
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
2 shared publications - Bruna Ferreira-Lomba
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal
2 shared publications - Daniela Cunha‐Garcia
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
2 shared publications - Daniela Monteiro-Fernandes
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal
2 shared publications
Latest Publications
- Open Access
The 5-HT 1A receptor agonist NLX-112 rescues motor swimming deficits in Spinocerebellar Ataxia type 3 mice
Introduction: Spinocerebellar ataxia 3 (SCA3) is a rare neurodegenerative disorder which causes progressive motor disturbances. There is no approved drug treatment but selective activation of serotonin 5-HT 1A receptors may be a promising therapeutic strategy to attenuate ataxia symptoms. Methods: NLX-112, a highly selective 5-HT 1A full agonist, was tested in the CMVMJD135 transgenic mouse model of SCA3. NLX-112 (1.25 and 5 mg/kg/day) was administered BID intraperitoneally for 14 weeks starting when the mice were 12 weeks of age, i.e., after ataxia signs had become established. The motor swimming test (MST), where mice are required to swim to a raised platform, was used to evaluate the motor behavior of SCA3 mice and their performance was compared with that of wild-type (WT) mice. Results: Both doses of NLX-112 were well tolerated by the SCA3 mice, as assessed by welfare parameters. In the MST, the latency of SCA3 mice to reach the platform was significantly longer than that of WT mice. However, when SCA3 mice were treated with either 1.25 or 5 mg/kg/day of NLX-112, they showed robust improvement of motor performance, with swimming latencies which were similar to those of WT mice. This effect of NLX-112 was maintained throughout the period of the study. Conclusions: The improved motor function of SCA3 mice when treated with NLX-112 supports its investigation as a drug candidate for the treatment of ataxia and related movement disorders. Graphical Highlights: Spinocerebellar ataxia type 3 (SCA3) is marked by progressive motor disturbances Targeting the serotonergic system is a promising strategy to treat SCA3 Transgenic SCA3 mice were treated with NLX-112, a selective 5-HT 1A agonist Chronic NLX-112 normalized performance of mice in the motor swimming test NLX-112 could constitute a drug candidate for treatment of the ataxia disorders
Open AccessThe 5-HT 1A receptor agonist NLX-112 rescues motor swimming deficits in Spinocerebellar Ataxia type 3 mice
Introduction: Spinocerebellar ataxia 3 (SCA3) is a rare neurodegenerative disorder which causes progressive motor disturbances. There is no approved drug treatment but selective activation of serotonin 5-HT 1A receptors may be a promising therapeutic strategy to attenuate ataxia symptoms. Methods: NLX-112, a highly selective 5-HT 1A full agonist, was tested in the CMVMJD135 transgenic mouse model of SCA3. NLX-112 (1.25 and 5 mg/kg/day) was administered BID intraperitoneally for 14 weeks starting when the mice were 12 weeks of age, i.e., after ataxia signs had become established. The motor swimming test (MST), where mice are required to swim to a raised platform, was used to evaluate the motor behavior of SCA3 mice and their performance was compared with that of wild-type (WT) mice. Results: Both doses of NLX-112 were well tolerated by the SCA3 mice, as assessed by welfare parameters. In the MST, the latency of SCA3 mice to reach the platform was significantly longer than that of WT mice. However, when SCA3 mice were treated with either 1.25 or 5 mg/kg/day of NLX-112, they showed robust improvement of motor performance, with swimming latencies which were similar to those of WT mice. This effect of NLX-112 was maintained throughout the period of the study. Conclusions: The improved motor function of SCA3 mice when treated with NLX-112 supports its investigation as a drug candidate for the treatment of ataxia and related movement disorders. Graphical Highlights: Spinocerebellar ataxia type 3 (SCA3) is marked by progressive motor disturbances Targeting the serotonergic system is a promising strategy to treat SCA3 Transgenic SCA3 mice were treated with NLX-112, a selective 5-HT 1A agonist Chronic NLX-112 normalized performance of mice in the motor swimming test NLX-112 could constitute a drug candidate for treatment of the ataxia disorders
- Open Access
Efficacy of chronic 5-HT 1A receptor agonism by NLX-112 in a mouse model of Spinocerebellar Ataxia type 3
Background: Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder caused by an elongated polyglutamine (polyQ) sequence in the ataxin-3 protein. This expansion triggers neuropathological events, leading to progressive motor disturbances. Currently, no approved therapy exists for this debilitating condition, but compelling evidence suggests that targeting the serotonergic system can significantly attenuate SCA3 disease progression in animal models. Objective: This study aimed to assess the effects of NLX-112, a highly selective serotonin 1A receptor (5-HT 1A R) full agonist, in the CMVMJD135 transgenic mouse model of SCA3. Methods: NLX-112 (0.625 and 5 mg/kg/day) and tandospirone (a 5-HT 1A R partial agonist used as a comparator; 20 and 80 mg/kg/day) were administered chronically in drinking water for 34 weeks, starting prior to symptom onset. To evaluate the effects of the drugs on SCA3 mice, motor-related behavioral tests and neuropathological techniques were employed. Results: Treatment with the higher dose of NLX-112 led to improvements in motor coordination and balance, and slowing of symptom deterioration as the disease progressed. These beneficial effects were not achieved with tandospirone. NLX-112 treatment also elicited neuroprotective effects, reducing dopaminergic (tyrosine hydroxylase-positive) cell loss and astrocyte reactivity in the substantia nigra. Conclusions: NLX-112 treatment, started pre-symptomatically, enhanced motor function, slowed disease progression and elicited neuroprotective effects in SCA3 mice, supporting its further development as a drug candidate for treatment of ataxia and related movement disorders. Graphical Key findings: NLX-112 attenuated motor deficits of SCA3 mice, when administered chronically prior to disease onset. NLX-112 reduced neuropathological biomarkers in SCA3 mice, namely by restoring dopaminergic neuron loss and decreasing astrocyte reactivity. NLX-112 is a potential candidate for addressing ataxia-related deficits in SCA3 patients.
Open AccessEfficacy of chronic 5-HT 1A receptor agonism by NLX-112 in a mouse model of Spinocerebellar Ataxia type 3
Background: Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder caused by an elongated polyglutamine (polyQ) sequence in the ataxin-3 protein. This expansion triggers neuropathological events, leading to progressive motor disturbances. Currently, no approved therapy exists for this debilitating condition, but compelling evidence suggests that targeting the serotonergic system can significantly attenuate SCA3 disease progression in animal models. Objective: This study aimed to assess the effects of NLX-112, a highly selective serotonin 1A receptor (5-HT 1A R) full agonist, in the CMVMJD135 transgenic mouse model of SCA3. Methods: NLX-112 (0.625 and 5 mg/kg/day) and tandospirone (a 5-HT 1A R partial agonist used as a comparator; 20 and 80 mg/kg/day) were administered chronically in drinking water for 34 weeks, starting prior to symptom onset. To evaluate the effects of the drugs on SCA3 mice, motor-related behavioral tests and neuropathological techniques were employed. Results: Treatment with the higher dose of NLX-112 led to improvements in motor coordination and balance, and slowing of symptom deterioration as the disease progressed. These beneficial effects were not achieved with tandospirone. NLX-112 treatment also elicited neuroprotective effects, reducing dopaminergic (tyrosine hydroxylase-positive) cell loss and astrocyte reactivity in the substantia nigra. Conclusions: NLX-112 treatment, started pre-symptomatically, enhanced motor function, slowed disease progression and elicited neuroprotective effects in SCA3 mice, supporting its further development as a drug candidate for treatment of ataxia and related movement disorders. Graphical Key findings: NLX-112 attenuated motor deficits of SCA3 mice, when administered chronically prior to disease onset. NLX-112 reduced neuropathological biomarkers in SCA3 mice, namely by restoring dopaminergic neuron loss and decreasing astrocyte reactivity. NLX-112 is a potential candidate for addressing ataxia-related deficits in SCA3 patients.
- 9 March 2022
- Published by Elsevier in Neuropharmacology
- Vol. 210, 109025
NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques
- 9 March 2022
- Published by Elsevier in Neuropharmacology
- Vol. 210, 109025
NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques
- 9 December 2020
- Published by Royal Society of Chemistry (RSC)
- p. 175-197
Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia
SEP-363856, a novel, first-in-class drug treatment being developed by Sunovion Pharmaceuticals, showed robust therapeutic effects in patients diagnosed with schizophrenia across a broad range of disabling symptoms including positive, negative, depressive, and general psychopathology symptoms, with a safety profile similar to placebo. SmartCube® – PsychoGenics’ proprietary mouse-based phenotypic platform, in combination with anti-target screening, was used as part of a phenotypic screening effort that identified SEP-363856. SmartCube® employs computer vision and artificial intelligence to extract and analyze behavioral data for central nervous system disorders. SEP-363856 does not interact with dopamine D2 nor with 5HT2A receptors that mediate the effects of currently available antipsychotic agents. The SmartCube® platform thus represents an effective approach to the discovery and development of the next generation of breakthrough treatments for schizophrenia and other neuropsychiatric disorders.
- 9 December 2020
- Published by Royal Society of Chemistry (RSC)
- p. 175-197
Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia
SEP-363856, a novel, first-in-class drug treatment being developed by Sunovion Pharmaceuticals, showed robust therapeutic effects in patients diagnosed with schizophrenia across a broad range of disabling symptoms including positive, negative, depressive, and general psychopathology symptoms, with a safety profile similar to placebo. SmartCube® – PsychoGenics’ proprietary mouse-based phenotypic platform, in combination with anti-target screening, was used as part of a phenotypic screening effort that identified SEP-363856. SmartCube® employs computer vision and artificial intelligence to extract and analyze behavioral data for central nervous system disorders. SEP-363856 does not interact with dopamine D2 nor with 5HT2A receptors that mediate the effects of currently available antipsychotic agents. The SmartCube® platform thus represents an effective approach to the discovery and development of the next generation of breakthrough treatments for schizophrenia and other neuropsychiatric disorders.
- 23 March 2018
- Published by Springer Nature in Neurochemical Research
- Vol. 43 (5) , 1035-1046
Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats
Peak-dose dyskinesia is associated with the dramatic increase in striatal dopamine levels that follows l-DOPA administration. The ‘false neurotransmitter’ hypothesis postulates that the latter is likely due to an aberrant processing of l-DOPA by serotonergic neurons. In keeping with this hypothesis, two highly selective ‘biased agonists’ of 5-HT1A receptors—namely F13714 and F15599 (NLX-101)—were recently shown to exhibit exceptionally potent anti-dyskinetic activity without impairing l-DOPA therapeutic properties despite their differential targeting of 5-HT1A receptor sub-populations. In this study, we investigated whether these two compounds dampened peak l-DOPA-induced dopamine microdialysate levels in the striatum of hemi-parkinsonian rats. Acute administration of either F13714 (0.04 and 0.16 mg/kg i.p.) or F15599 (0.16 and 0.64 mg/kg, i.p.) blunted l-DOPA (2 mg/kg)-induced increases in dopamine microdialysate levels in the denervated striatum (following unilateral injection of 6-OHDA into the medial forebrain bundle). No significant changes were observed on the intact side of the brain. Concurrently, both drugs profoundly reduced striatal serotonin levels on both sides of the brain. In addition, F13714 and F15599, in the presence of l-DOPA, produced a dose-dependent increase in glutamate levels, but this effect was restricted to later time points. These finding support the interpretation that F13714 and F15599 mediate their anti-dyskinetic effects by blunting of the peak in dopamine levels via activation of somatodendritic serotonin 5-HT1A receptors and the consequent inhibition of serotonergic neurons. This study adds to the growing body of evidence supporting the development of a potent 5-HT1A receptor agonist for treatment of peak-dose dyskinesia.
- 23 March 2018
- Published by Springer Nature in Neurochemical Research
- Vol. 43 (5) , 1035-1046
Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats
Peak-dose dyskinesia is associated with the dramatic increase in striatal dopamine levels that follows l-DOPA administration. The ‘false neurotransmitter’ hypothesis postulates that the latter is likely due to an aberrant processing of l-DOPA by serotonergic neurons. In keeping with this hypothesis, two highly selective ‘biased agonists’ of 5-HT1A receptors—namely F13714 and F15599 (NLX-101)—were recently shown to exhibit exceptionally potent anti-dyskinetic activity without impairing l-DOPA therapeutic properties despite their differential targeting of 5-HT1A receptor sub-populations. In this study, we investigated whether these two compounds dampened peak l-DOPA-induced dopamine microdialysate levels in the striatum of hemi-parkinsonian rats. Acute administration of either F13714 (0.04 and 0.16 mg/kg i.p.) or F15599 (0.16 and 0.64 mg/kg, i.p.) blunted l-DOPA (2 mg/kg)-induced increases in dopamine microdialysate levels in the denervated striatum (following unilateral injection of 6-OHDA into the medial forebrain bundle). No significant changes were observed on the intact side of the brain. Concurrently, both drugs profoundly reduced striatal serotonin levels on both sides of the brain. In addition, F13714 and F15599, in the presence of l-DOPA, produced a dose-dependent increase in glutamate levels, but this effect was restricted to later time points. These finding support the interpretation that F13714 and F15599 mediate their anti-dyskinetic effects by blunting of the peak in dopamine levels via activation of somatodendritic serotonin 5-HT1A receptors and the consequent inhibition of serotonergic neurons. This study adds to the growing body of evidence supporting the development of a potent 5-HT1A receptor agonist for treatment of peak-dose dyskinesia.